Amolyt Pharma was a clinical-stage biopharmaceutical company based in Lyon, France. The company had pipeline of potential best-in-class treatments for metabolic disorders. Its lead compound was precisely designed agonist against parathyroid receptor for the treatment of hypoparathyroidism. In 2024, Amolyt Pharma was acquired by AstraZeneca for $1.05B USD.
Hypoparathyroidism
CTI LSF III
Syndicate
n/a
January 21, 2023
Amolyt Pharma acquired by Alexion for $1.05B USD
Series C
Amolyt’s parathyroid receptor agonist is specifically designed to bind to the calcium channel in the kidney and not in the bone, thus restoring serum calcium level without affecting deteriorating bone
January 6, 2023
